Paxalisib - Kazia Therapeutics
Alternative Names: G-02441729; GDC-0084; RG 7666; SIM-0395Latest Information Update: 08 Oct 2024
At a glance
- Originator Genentech
- Developer Alliance for Clinical Trials in Oncology; Dana-Farber Cancer Institute; Genentech; Global Coalition for Adaptive Research; Huntsman Cancer Institute; John Hopkins University; Kazia Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California; Weill Cornell Medical College
- Class Amines; Antineoplastics; Morpholines; Oxazines; Purines; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Glioblastoma
- Phase II Brain metastases; Glioma; Lymphoma
- Phase I/II Cancer
- Preclinical Malignant melanoma; Rhabdoid tumour
- No development reported Diffuse intrinsic pontine glioma; Meningeal carcinomatosis
Most Recent Events
- 02 Oct 2024 Efficacy and adverse event data from a phase II trial in Brain Metastases and Leptomeningeal Metastasisreleased by Kazia Therapeutics
- 12 Sep 2024 Kazia Therapeutics in-licenses IP from QIMR Berghofer for PI3K Combination Therapies
- 10 Jul 2024 Phase-I/II clinical trials in Cancer (Combination therapy, Second-line therapy or greater, In adolescents, In adults, In children, In infants, In neonates) in Canada, Australia (PO) (NCT06208657)